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Purpose/Objective: Prognosis in recurrent glioblastoma is 
very poor with survival of 3-6 months. Bevacizumab,a 
humanized VEGF monoclonal antibody, exhibits evidence of 
apparent antitumor benefit, although these data remain 
controversial. We analyze a group of sequential patients in 
which Bevacizumab was used as off-label drug combined with 
chemotherapy and low dose radiation therapy (LDRT). 
The aim is to evaluate feasibility, tolerance and response. 
Materials and Methods: We enrolled patients (KPS > 70,age 
>18 years) with recurrent GBM after Temozolomide. 
Bevacizumab (10 mg/m2 every 14 days) was administered 
alone or in combination with Fotemustine (100 mg/m2 2nd day 
every 14 days) or Irinotecan (125 mg/m2 every 14 days) 
Lomustine (110 mg/m2 every 6 weeks). 
LDRT (0.60 Gy twice daily) was administrated at least 4 hours 
apart, for 2 days every 14 days; 5 cycles were planned. 
Clinical Target Volume included the tumor with surgical 
cavity, plus a 30-mm margin.  
Toxicity was evaluated according to the Common 
Terminology Criteria for Adverse Events version 4.0; response 
was based on RECIST Guidelines; the overall survival (OS) and 
the progression-free survival (PFS) was calculated by the 
Kaplan-Mayer method. 
Results: We enrolled 34 patients from July 2011 to February 
2014; median age at the time of recurrence was 52 years 
(range 22-77) with a median time to recurrence of 11.76 
months ( range 3.25-102.6).  
Twentyfive out of 34 pts (73.5 %) received Bevacizumab plus 
Fotemustine, 3/34 (8.8%) Bevacizumab with Irinotecan, 3/34 
(8.8%) Bevacizumab with Lomustine and 2/34 (5.8%) 
Bevacizumab alone, instead 15/34(44%) received LDRT. 
Median dose of LD-RT was 960 cGy (range 480-2400 cGy).  
Bevacizumab was prescribed in14/34 at the first relapse, in 
15/34 (44%) at the second progression and in 5/34 (14.7%) at 
the third one. 
Grade 1-2 of leukopenia and/or thrombocytopenia were 
recorded in 6/34 pts (17.6%), and G3-4 in 8/34pts (23.5%). In 
one case we observed a cerebral haemorrhage. After 5 cicles 
we observed 2 complete response (5.8%), 5 partial responses 
(14.7%), 5 stable diseases (14.7%), and 17 progression 
diseases (50%). 
With a median follow up from recurrence of 41 months (range 
16-130), 7 patients(20.6%) are alive with disease and 27 are 
died(79.4%). Median OS and PFS from first progression were 
26,4 and 11,76 months respectively. 
No statistically differences was observed in OS (p= 0.97) and 
PFS ( p= 0.16) with or without LDRT. 
Conclusions: Bevacizumab in combination with LD-RT and 
chemotherapy is feasible and quite well tolerated; but 
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Purpose/Objective: The optimal treatment approach for 
recurrent glioblastoma multiforme (rGBM) in elderly and/or 
frail patients (pts) remains virtually unexplored and the best 
supportive care (BSC) only is often considered appropriate 
due to the very poor prognosis. The aim of this study was to 
evaluate the impact of different treatment methods on post-
progression survival (PPS) and overall survival (OS) of such 
pts. 
Materials and Methods: We performed a retrospective 
analysis of the data from 100 pts treated between 2010 and 
2013 within the phase III IAEA study NCT1450449 which 
compared one-week with a standard three-week radiotherapy 
(RT) regimen in elderly and/or frail pts with GBM (Frail: ≥50 
years, KPS 50 – 70; Elderly and frail: ≥65 years, KPS 50 – 70; 
Elderly: ≥65 years, KPS 80 – 100). Date and site of relapse, 
KPS at relapse and treatment of relapse – surgery, RT, 
chemotherapy (CHT) or BSC only, were recorded. Kaplan-
Meier method was used to estimate PPS and OS rates for 
different treatment modalities; subgroups were compared 
with the log-rank test. 
Results: Eighty-four out of 100 pts (41 after one-week RT; 43 
after three-week RT) enrolled in the study experienced a 
relapse. At progression, 47 pts (56%) received BSC only, 21 
(25%) received CHT, 8 (9.5%) received surgery (two of them: 
surgery + CHT, one: surgery + RT), three pts (3.5%) received 
RT, for 5 (6%) pts no such data was available. Median 
progression free survival from randomization was 16 weeks, 
15 weeks for the group of pts who received any treatment of 
recurrence and 16 weeks for the group with BSC (p = 0.89). 
Baseline characteristics were similar in the two groups, 
except for the extent of the primary surgery – all pts who 
received any treatment of recurrence had undergone primary 
total (35%) or subtotal (65%) resection, whereas in the group 
with BSC 25% had had biopsy only, 61% had subtotal and 17% 
had total resection, p = 0.01. After a median post progression 
follow-up of 13 weeks (range: 0 – 78), 74 pts (88%) have died, 
median PPS was 15 weeks. Median PPS for pts who received 
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any treatment was 23 weeks vs. 9 weeks in pts with BSC, 
p<0.0001. In pts who received local treatment (8: surgery + 
3: RT) median PPS was 51 vs. 21 weeks for CHT, p = 0.36. 
Median PPS for surgery was 51 weeks vs. 17 weeks for RT, p = 
0.62. Pts with poor KPS (<60) at relapse did not benefit from 
local treatment as compared with CHT: median PPS for local 
treatment vs. CHT was 14 vs. 18 weeks, p = 0.81. Median PPS 
for poor KPS pts with BSC was 7 weeks. For the whole group 
of 84 pts, median OS from randomization was 35 weeks: 55 
vs. 30 weeks in pts who received any treatment vs. BSC only, 
p < 0.0001. 
 
 
Conclusions: Our results suggest that an active therapeutic 
approach may be beneficial for selected elderly and/or frail 
pts with rGBM, compared to BSC alone. Re-surgery seems to 
be the most efficacious therapeutic option for rGBM in 
elderly pts with high KPS; in poor KPS pts there is no benefit 
of local treatment (surgery and/or RT) over CHT.  
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Purpose/Objective: To report on outcomes and toxicity after 
proton beam radiotherapy for large non-peripapillary 
choroidal melanoma considered unsuitable for other eye-
sparing therapies in Canada. 
Materials and Methods: We included patients with non-
peripapillary tumors (>2mm from the optic disc) treated with 
proton therapy at TRIUMF, the only ocular proton therapy 
facility in Canada, from 1995-2013. A prospective database 
including patient, tumor, and treatment characteristics was 
updated with ocular complications and follow up status from 
chart reviews. 
Results: In total, 77 patients were included in the analysis. 
The median age was 60 years and the median observation 
time 47 months (0-221 months). More than half of the 
patients (53%) had a tumor located anterior to the equator 
and 35% had involvement of the ciliary body. The median 
tumor diameter was 13.6 mm and the median thickness was 
7.1 mm. The 5 -(10) year actuarial rate was 85 (85)% for 
ocular tumor control, 72 (57)% for metastasis-free survival, 
77 (63)% for overall survival, 22 (22)% for enucleation and 38 
(38)% for complete blindness. 80% of patients with blindness 
had developed neovascular glaucoma. 
For patients with good vision (≥20/50) at baseline, the 5-(10) 
year actuarial rate was 40 (40)% for conservation of vision of 
20/50 or better, 44 (44)% for conservation of vision of 20/200 
or better and 67 (67)% for conservation of vision of counting 
fingers or better.  
On univariate analysis, patients with ciliary body involvement 
had significant worse metastasis-free survival and overall 
survival rates compared to patients without ciliary body 
involvement (p<0.001). 
Conclusions: Proton therapy resulted in acceptable local 
control and survival rates in patients with large anteriorly 
located tumors. The risk of complete blindness and severe 
toxicity requiring enucleation was low and a substantial 
proportion maintained a useful vision.  
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Purpose/Objective: * RECTAL BOOST = RandomizEd 
Controlled Trial for pre-operAtive dose-escaLation BOOST in 
locally advanced rectal cancer. 
Randomized controlled trials (RCTs) are the gold standard to 
evaluate effectiveness of new interventions. RCTs often 
experience difficulties in recruitment and generalizability. 
We introduced the 'cohort multiple Randomized Controlled 
Trial' (cmRCT) to efficiently and simultaneously evaluate 
multiple oncologic of interventions, while maintaining the 
highest level of evidence. 
The RECTAL BOOST* study, which compares response rates 
after boost plus standard chemoradiation (CRT) (intervention 
arm) to standard chemoradiation alone (control arm) in 
patients with locally advanced rectal cancer (LARC), is the 
first clinical study according to cmRCT design. We evaluated 
feasibility of this design in terms of recruitment rates and 
boost-offer acceptance. 
Materials and Methods: The basis of this 'cohort multiple 
Randomized Controlled Trial' (cmRCT) is a cohort consisting 
of all patients with rectal cancer. Patients consent to 
prospective collection of clinical, histological and quality-of-
